Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy

BACKGROUND: Adoptive cell therapy (ACT) using genetically modified T cells has evolved into a promising treatment option for patients with cancer. However, even for the best-studied and clinically validated CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, many patients face the challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboelella, Nada S, Brandle, Caitlin, Okoko, Ogacheko, Gazi, Md Yeashin, Ding, Zhi-Chun, Xu, Hongyan, Gorman, Gregory, Bollag, Roni, Davila, Marco L, Bryan, Locke J, Munn, David H, Piazza, Gary A, Zhou, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330341/
https://www.ncbi.nlm.nih.gov/pubmed/35882449
http://dx.doi.org/10.1136/jitc-2022-004938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330341/
https://www.ncbi.nlm.nih.gov/pubmed/35882449
http://dx.doi.org/10.1136/jitc-2022-004938

Ejemplares similares